Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2004

View Archived Issues

CHMP adopts extension of indication for Schering-Plough HCV products

Merck researchers describe new anti-HIV vaccines

New Eg5 kinesin inhibitors developed by AstraZeneca researchers

Novel JNK inhibitors and their use reported by Eisai

Agents combining antimitotic, antiangiogenic and PDE4 activity claimed by Celgene

Novel MCH receptor antagonists prepared and tested at Schering-Plough

Roche claims new 5-HT6 receptor ligands for cognitive disorders, psychosis, etc.

Urea-based glycogen phosphorylase a inhibitors newly developed at Aventis

New 5-HT2C receptor modulators under study at GSK

Series B financing at Othera to accelerate pipeline development

Japanese approval sought for Advate

Final approval and first-to-file status for Alpharma's gabapentin

Phase II study for Levulan Kerastick in acne

Spiriva approved for Japanese import

Dacogen MAA accepted for review

Japanese approval for Trisenox

Urocortin 2 evaluated in new phase I study

Evoclin approved for acne vulgaris

Velac NDA accepted for filing

Ivax signs U.S. agreement for citicoline

Emerging companies showcased at the 12th Annual BioPartnering Europe conference: Austrianova

Emerging companies showcased at the 12th Annual BioPartnering Europe conference: Ionix

Nociceptin opioid receptor antagonist may be useful in the management of addictive disorders

Improved nucleoside triphosphate analogue promising against HCV infection

Reversal of multidrug resistance in tumor cells by FG-020318

TAS-108 evaluated in advanced breast cancer

Fampridine-SR active in multiple sclerosis

Studies reveal teriflunomide efficacy in treating multiple sclerosis

Superoxide-driven nitration of endogenous MnSOD critical in NMDA-mediated hyperalgesia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...